BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $15,805.53 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 711 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $22.23, for a total value of $15,805.53. Following the sale, the insider now owns 78,721 shares in the company, valued at approximately $1,749,967.83. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Tuesday, June 10th, Sarah Aebersold sold 235 shares of BioLife Solutions stock. The shares were sold at an average price of $23.70, for a total value of $5,569.50.
• On Wednesday, May 28th, Sarah Aebersold sold 217 shares of BioLife Solutions stock. The shares were sold at an average price of $22.46, for a total value of $4,873.82.
• On Wednesday, April 9th, Sarah Aebersold sold 210 shares of BioLife Solutions stock. The shares were sold at an average price of $20.11, for a total transaction of $4,223.10.
• On Tuesday, April 1st, Sarah Aebersold sold 5,771 shares of BioLife Solutions stock. The stock was sold at an average price of $22.66, for a total transaction of $130,770.86.

BioLife Solutions Stock Performance

NASDAQ:BLFS traded down $0.22 on Wednesday, hitting $21.52. The stock had a trading volume of 757,214 shares, compared to its average volume of 408,607. The business's 50-day simple moving average is $22.73 and its two-hundred day simple moving average is $24.88. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -74.20 and a beta of 1.82. BioLife Solutions, Inc. has a 52-week low of $18.70 and a 52-week high of $29.55. The company has a quick ratio of 3.74, a current ratio of 4.73 and a debt-to-equity ratio of 0.01.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The company had revenue of $23.94 million for the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. As a group, research analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in shares of BioLife Solutions in the fourth quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions during the 4th quarter valued at $31,000. State of Wyoming lifted its stake in shares of BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 1,490 shares in the last quarter. US Bancorp DE lifted its stake in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after buying an additional 1,528 shares in the last quarter. Finally, 1620 Investment Advisors Inc. boosted its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after buying an additional 675 shares during the period. Institutional investors own 93.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.